RGX-314
Wet Age-Related Macular Degeneration (wAMD)
Key Facts
About ReGenX Biosciences
ReGenX Biosciences is a clinical-stage biotechnology company dedicated to improving lives through the development of curative gene therapies. Its core asset is the NAV Technology Platform, a collection of over 100 novel AAV vectors that have become industry standards, powering its own pipeline and over 20 partnered programs, including the commercial therapy Zolgensma®. The company's dual-strategy of internal development and broad licensing has established a significant revenue stream and validates its platform's utility across multiple therapeutic areas.
View full company profileAbout ReGenX Biosciences
ReGenX Biosciences is a clinical-stage biotechnology company dedicated to improving lives through the development of curative gene therapies. Its core asset is the NAV Technology Platform, a collection of over 100 novel AAV vectors that have become industry standards, powering its own pipeline and over 20 partnered programs, including the commercial therapy Zolgensma®. The company's dual-strategy of internal development and broad licensing has established a significant revenue stream and validates its platform's utility across multiple therapeutic areas.
View full company profileAbout REGENXBIO
REGENXBIO is a clinical-stage biotech with a mission to deliver life-changing gene therapies through its foundational NAV Technology Platform. Its achievements include enabling the blockbuster therapy ZOLGENSMA® and building a diverse internal pipeline, most notably in MPS II and Duchenne muscular dystrophy. The company's strategy combines internal development of wholly-owned assets with a high-margin, capital-efficient licensing model that provides recurring revenue and validates its technology.
View full company profileAbout REGENXBIO
REGENXBIO is a clinical-stage biotech with a mission to deliver life-changing gene therapies through its foundational NAV Technology Platform. Its achievements include enabling the blockbuster therapy ZOLGENSMA® and building a diverse internal pipeline, most notably in MPS II and Duchenne muscular dystrophy. The company's strategy combines internal development of wholly-owned assets with a high-margin, capital-efficient licensing model that provides recurring revenue and validates its technology.
View full company profileTherapeutic Areas
Other Wet Age-Related Macular Degeneration (wAMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| UBX1325 (foselutoclax) | Unity Biotechnology | Phase 2 |
| Undisclosed Aptamer Program | Drive Therapeutics | Pre-clinical |